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San Francisco, CaliforniaABSTRACT Dysfunction of pulmonary surfactant in the lungs is associated with respiratory pathologies such as acute
respiratory distress syndrome or meconium aspiration syndrome. Serum, cholesterol, and meconium have been described
as inhibitory agents of surfactant’s interfacial activity once these substances appear in alveolar spaces during lung injury and
inflammation. The deleterious action of these agents has been only partly evaluated under physiologically relevant conditions.
We have optimized a protocol to assess surfactant inhibition by serum, cholesterol, or meconium in the captive bubble sur-
factometer. Specific measures of surface activity before and after native surfactant was exposed to inhibitors included i), film
formation, ii), readsorption of material from surface-associated reservoirs, and iii), interfacial film dynamics during compres-
sion-expansion cycling. Results show that serum creates a steric barrier that impedes surfactant reaching the interface.
A mechanical perturbation of this barrier allows native surfactant to compete efficiently with serum to form a highly surface-active
film. Exposure of native surfactant to cholesterol or meconium, on the other hand, modifies the compressibility of surfactant films
though optimal compressibility properties recover on repetitive compression-expansion cycling. Addition of polymers like
dextran or hyaluronic acid to surfactant fully reverses inhibition by serum. These polymers also prevent surfactant inhibition
by cholesterol or meconium, suggesting that the protective action of polymers goes beyond the mere enhancement of interfacial
adsorption as described by depletion force theories.INTRODUCTIONPulmonary surfactant is a complex mixture of lipids and
proteins lining the alveolar air-water interface (1,2). Inhibi-
tion of pulmonary surfactant action is associated with many
respiratory diseases, rendering surfactant dysfunctional
and affecting lung compliance and gas exchange. Acute
respiratory distress syndrome (ARDS) develops after
different lung injuries like pneumonia, aspiration of gastric
contents, near-drowning, or edema. In ARDS, alveoli are
filled with protein-enriched edema fluid, which impairs
surfactant action. ARDS causes 60,000 deaths per year in
the USA (3,4). Meconium aspiration syndrome also remains
an important cause of morbidity and mortality affecting
>20,000 neonates per year in the United States. Meconium
aspiration syndrome is characterized by airway obstruction,
pneumonitis, pulmonary hypertension, acidosis, and hypox-
emia (5). Common to these diseases is surfactant inacti-
vation. Studying and understanding the mechanisms of
inhibition of surfactant is important not only for under-
standing the respiratory pathophysiology, but also for devel-
oping new strategies for treatment.
Three main functions determine the activity of surfactant
preparations and the impact of inhibition. First, surfactant
must adsorb quickly (in a few seconds) to reduce interfacial
surface tension. Second, surfactant must be efficiently reab-
sorbed to the air-subphase interface (as occurs during inspi-Submitted March 7, 2012, and accepted for publication August 6, 2012.
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0006-3495/12/10/1451/9 $2.00ration in alveoli), and finally surfactant must form rigid
films on compression of the surface (as occurs during expi-
ration), which exhibit low surface tension. Inhibition of
surfactant may impair adsorption (e.g., as with serum)
(6–8), or cause perturbation of the composition and struc-
ture of surfactant films (e.g., by cholesterol or bile salts)
(9–11), which prevents attainment of maximally com-
pressed states.
The surface behavior of pulmonary surfactant and the
mechanisms by which it is altered by different inhibitory
substances have been analyzed using different approaches,
including Langmuir surface balances (12), the pulsating
bubble surfactometer (13–15), axisymmetric drop shape
analysis in conjunction with constrained sessile drop surfac-
tometry (16), or the captive bubble surfactometer (CBS)
(8,17–19). Limitations of these methods prevent study of
inhibition under (patho) physiologically relevant conditions
that include temperature and humidity, high concentrations
of both surfactant and inhibitory substances, and alveolar
geometry.
For a variety of reasons, inhibition has been difficult to
study in the CBS (9). In this study, we have modified the
method of application of the sample to simulate competition
between serum proteins and surfactant complexes for the
interface (6–8,20). Traditionally, serum has been introduced
into the subphase in which the bubble is formed. We have
applied undiluted serum onto the surface of the bubble
thus allowing serum proteins to form a concentrated film
at the interface before the application of surfactant. Surfacehttp://dx.doi.org/10.1016/j.bpj.2012.08.024
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Although the actual concentration of serum leaked into an
injured lung is difficult to establish, testing a layer at high
concentrations of serum mimics the most potentially harm-
ful condition. Surfactant is then applied near the surface of
the bubble, instead of directly onto the surface of the bubble
as it has been done in the past. Therefore, surfactant finds
a steric barrier to adsorption, as would happen in vivo after
surfactant is freshly secreted by pneumocytes, and must
traverse a serum layer in an injured and edematous alveolus
to adsorb at the interface. Similarly, exogenous surfactant
introduced via the trachea as therapy, must also find its
way to the alveolar interface through the leaky, inflamed
interior of the lung.
To study meconium/cholesterol inhibition we premixed
and incubated each with surfactant to allow these inhibitors
to incorporate into surfactant complexes, because the main
inhibitory mechanism for both agents is disruption of
surfactant structure (8,9). In a lung full of serum or meco-
nium, surfactant may suffer dilution. Therefore, we also
studied various surfactant concentrations. For inhibition
experiments, we use critical conditions, that is to say, low
concentrations of surfactant, which are still functional but
susceptible to inhibition. The concentration of surfactant
in the subphase of healthy alveoli is estimated at ~30–
100 mg/mL. However, during inflammation, reduced pro-
duction by damaged epithelia, an accelerated catabolism
by lipases and proteases, and dilution by edema, all con-
tribute to a substantial decrease of surfactant concentrations.
By optimizing the CBS technique, we have been able to
study and compare inhibition by serum, meconium, and
cholesterol, under more restrictive conditions than assessed
previously. We have confirmed that serum imposes a steric
barrier to surfactant adsorption, which effectively competes
with native surfactant to reach the interface. Exposure
to cholesterol or meconium alters the compressibility of
surfactant films. Surprisingly, addition of polymers such
as dextran or hyaluronic acid (HA) prevents surfactant inhi-
bition both by serum, and by meconium or cholesterol
despite differing mechanism of inhibition.MATERIALS AND METHODS
Materials
Native porcine lung surfactant (NS) was purified from bronchoalveolar
lavage by NaBr density gradient centrifugation as previously described
(6). Isolated surfactant was used in aqueous suspensions without organic
extraction. Native surfactant contains a full complement of surfactant
proteins SP-A, SP-B, and SP-C. Its concentration was measured by analysis
of lipid phosphorous (23). Surfactant amounts and concentrations are ex-
pressed as phospholipid mass, taking 750 Da as the average phospholipid
molecular mass. Three different batches of native surfactant were used in
different experiments. Dilutions of material were made with 5 mM Tris
pH 7 buffer, containing 150 mM NaCl. First passed meconium from term
infants was collected, pooled, and lyophilized. Dry meconium was diluted
in Tris buffer and mixed with surfactant at a final concentration of 10 mg/mlBiophysical Journal 103(7) 1451–1459for both.Water-soluble cholesterol (complexedwithmethyl-b-cyclodextrine
(MbCD)) was obtained from Sigma (C4951, St. Louis, MO) and mixed
(at final proportion of 4% cholesterol w/w) with surfactant. We determined
that exposure of NS to cholesterol-loaded MbCD increases the proportion
of cholesterol from 3.1 5 0.2% to 5.8 5 0.8% (w/w), (average of three
experiments (10)). Porcine serum was obtained from blood and used at
a protein concentration of 100 mg/ml. Hyaluronic acid (HA, 120 k) and
dextran (Dex, 148 k) were obtained from Sigma and mixed at final concen-
trations of 0.25% for HA and 5% dextran (w/v) with surfactant.Captive bubble surfactometry
Surfactant at 37C was evaluated as described previously (19,24). The
chamber contained 5 mM Tris-HCl pH7, 150 mM NaCl, and 10% sucrose.
After a small air bubble (0.035–0.040 cm3) was formed, ~150 nL of surfac-
tant (10 mg/ml) was deposited below the bubble surface with a transparent
capillary. Following the introduction of surfactant, the change in surface
tension (g) was monitored over 5 min from changes in shape of the bubble
(17). The chamber was then sealed and the bubble was rapidly (1 s)
expanded to 0.15 cm3, to record postexpansion adsorption. 5 min after
expansion, quasistatic cycles started, where the bubble size was first
reduced (by 20% of its previous volume) and then enlarged in a stepwise
fashion. There was 1 min intercycle delay between each of four quasistatic
cycles and a further 1 min delay before starting dynamic cycles, in which
the bubble was continuously varied at 20 cycles/min. Data from initial
and postexpansion adsorption are presented as averages from three experi-
ments, whereas graphs plotting quasistatic (Q-static) and dynamic cycles
correspond to single representative experiments. Data from replicates are
shown in the tables (see Supporting Material).
To study serum inhibition we first injected serum to form a layer at the
air-liquid interface, and then injected surfactant in the subphase. To study
meconium or cholesterol inhibition, inhibitor and surfactant were premixed,
and then the mixtures were injected into the subphase. We used a concentra-
tion of surfactant of 10 mg/ml. In additional experiments, polymers were
premixed with surfactant and immediately injected into the subphase as
described previously.Data reproducibility and statistics
Figures represent the mean 5 SD after averaging data from three ex-
periments. CBS compression-expansion experiments are shown as repre-
sentative isotherms. Significance was determined by t-Student test. The
Holm-Sidak method was applied for multiple comparisons with a signifi-
cance level < or ¼ 0.05.RESULTS
To study changes in biophysical properties when inhibitory
agents are added to NS, we modified the usual CBS protocol
in threeways: First we tested relatively low concentrations of
surfactant, 10 mg/ml phospholipid, applying the sample
without contacting with the surface bubble (see images in
Fig. 1 a). Second, we injected undiluted serum near the
surface of the bubble. As a consequence of the high density
of the sucrose-containing subphase, the undiluted serum
forms a layer of concentrated material surrounding the
bubble. This can be observed when serum is doped with a
trace of fluorescently labeled albumin (see image in Fig. 1 b).
Fig. 2 shows the surface activity of a low concentration of
uninhibited NS. Surface tension decreased to 22.1 5
1.2 mN/m after 5 min of initial adsorption, and remained
FIGURE 1 CBSmodel to test surfactant inhibition by serum. (a) Sequential images of a surfactant sample immediately before (t¼ 0) and at different times
after injection underneath an air bubble at the CBS. (b) Fluorescence image of a serum sample doped with a trace of rhodamine-labeled albumin, injected
underneath the bubble at the CBS.
Polymer Reversal of Surfactant Inhibition 1453at 22.95 1.1 mN/m after expanding the bubble for 5 min.
Initial adsorption occurs within a few seconds (as described
by Schu¨rch et al.(19)). Fig. 2 also shows how serum (2 ml)
applied near the surface of the bubble decreases surface
tension to 45.45 2.4 mN/m after 5 min of initial adsorption
and to 49.5 5 2.3 mN/m after 5 min the expansion of the
bubble (7).
When we applied NS (10 mg/ml) underneath the pre-
formed serum film, without touching the bubble surface,
no adsorption of NS occurred (surface tension remained
39.8 5 3.3 mN/m, significantly higher than that reachedFIGURE 2 Interfacial adsorption of native surfactant in the absence or presen
kinetics of surfactant (NS) (black dots), serum alone (white dots), NS 10 mg/ml
(triangles), and NS 20 mg/ml applied underneath the bubble surface coated with
three experiments.by NS in the absence of serum). After expansion, the
minimal surface tension after 5 min also remained
unchanged 43.9 5 1.5 mN/m (Fig. 2). Fig. 2 also shows
that a concentration of surfactant of 20 mg/ml is not in-
hibited by serum. In other experiments, surfactant at
10 mg/ml was applied directly into the bubble surface,
thus breaking through the serum protein layer, resulting in
equilibrium surface tensions similar to noninhibited surfac-
tant (not shown).
Fig. 3 summarizes compression-expansion isotherms of
surfactant films formed in the absence or presence of serum.ce of serum. Initial (left panel) and post-expansion (right panel) adsorption
applied underneath the bubble surface coated with a preformed serum layer
serum (squares), all at 37C. Data are mean5 SD after averaging data from
Biophysical Journal 103(7) 1451–1459
FIGURE 3 Compression-expansion isotherms of native surfactant films in the absence or presence of serum. Q-static (upper panels) and dynamic (lower
panels) compression/expansion isotherms from surfactant films formed upon injection of NS at 10 or 20 mg/mL phospholipid, in the absence or in the
presence of a preformed serum layer. A representative experiment is shown here after repeating three independent experiments with each sample.
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(Q-static) and fast (Dynamic, physiological-like), cycling
regimes. Q-static cycling provides details on the intrinsic
compressibility properties of the films as they are formed
at the interface, including their potential to undergo
compression-driven reorganizations or to reach very low
surface tension under conditions permitting local or long-
range relaxation. Dynamic cycling mimics physiological-
like compression-expansion rates and allow testing surface
properties of films far from equilibrium but close to
breathing conditions. In the absence of serum, NS exhibits
well-characterized behavior, with the first quasistatic cycle
showing greater hysteresis than the subsequent cycles.
Thus, at the end of the fourth quasistatic cycle surface
tension is 1.6 5 0.6 mN/m after area compression of
~20% (see Table S1 in the Supporting Material). Reorgani-
zation of material during Q-static compression is something
we were not able to study at high surfactant concentrations,
25 or 72 mg/ml (17,19). Dynamic cycles show normal func-
tion of surfactant in the absence of serum, with very low
surface tension (1.8 5 0.7 mN/m) with less than a 20%
area reduction. In Fig. 3, the surface tension of a pure serum
layer under Q-static and dynamic conditions is never lower
than 37.85 2.4 mN/m. NS (10 mg/mL) applied just below
the surface of the bubble, underneath a preformed serum
layer, did not lower surface tension below 21.7 5
1.6 mN/m (Q-static) or 17.15 6.0 mN/m (dynamic cycles),
even after as much as a 50% reduction of surface area. These
values were always significantly higher than the surface
tension reached by NS applied in the same conditions inBiophysical Journal 103(7) 1451–1459the absence of serum. When we doubled the concentration
of surfactant, the film was still not able to reduce surface
tension below 20 mN/m under slow quasi-static compres-
sion-expansion cycling. However, if cycled quickly
(20 cycles/min), films made by concentrated surfactant
reduced tension below 10 mN/m during the first compres-
sion and reached minimal tensions below 5 mN/m with
very little compression in all the subsequent cycles. This
means that surfactant at concentrations R20 mg/mL
is only partly inhibited by undiluted serum when rapid
compression-expansion is imposed. We therefore used
10 mg/ml as an appropriate critical surfactant concentration
to study inhibition in the following experiments.
Figs. 4–6 show a summary of the inhibitory effect of
serum, meconium, or cholesterol on the surface behavior
of surfactant and the prevention of this inhibition by preex-
posure of surfactant to polymers such as HA (negatively
charged) or dextran (noncharged). Panel a of Fig. 4 illus-
trates how the presence of a preformed serum layer at the
bubble surface does not allow surfactant to reach the inter-
face, because the surface tension reached upon surfactant
injection is not lower than 40 mN/m. Application of surfac-
tant premixed with the polymers (HA 0.25% w/v or dextran
0.5% w/v) restores the ability of surfactant to reach the
interface and lower surface tension to 22–23 mN/m. Addi-
tion of the polymers by themselves does not affect inter-
facial adsorption of NS, as surfactant premixed with
polymers had surface tensions that were not significantly
different from the tensions reached by NS alone. The poly-
mers tested do not possess surface activity by themselves,
FIGURE 4 Interfacial adsorption of native surfactant in the absence or
presence of inhibitors and polymers. (a) Minimal surface tension upon
5 min of initial (black bars) or post-expansion (gray bars) adsorption of
a native surfactant sample combined or not with the indicated polymers,
injected under a clean or a serum-coated bubble. (b)Minimal surface tension
upon initial or post-expansion adsorption of surfactant in the absence or
presence of meconium, cholesterol, and/or polymers. Data are mean 5
SD after averaging three independent experiments from each sample.
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subphase does not produce changes in the surface tension
of the saline solution, either in the CBS or as tested in Lang-
muir troughs (not shown). To test inhibition of adsorption by
meconium or cholesterol, we premixed each with NS,
before applying the mixture near the surface of the bubble.
Fig. 4 (panel b) also illustrates that the equilibrium surface
tension reached upon adsorption, either initially or after
bubble expansion of meconium- or cholesterol-pretreated
surfactant, was not different from that of NS alone. It can
be noticed that the surface tension reached upon 5 min of
expansion of the bubble coated with NS premixed withmeconium is apparently higher, but with a rather large error
as a consequence of high heterogeneity in the behavior of
replicas, likely associated with the intrinsic complexity
and heterogeneity of meconium. Fig. 5 summarizes quasi-
static cycling of NS in the absence or in the presence of
serum, meconium, or cholesterol, with or without premixing
with dextran or HA. Q-static cycling of NS in the presence
of a serum film (2 ml, 100 mg/ml total protein) was highly
defective, with surface tension decaying only to 37.9 5
2.4 mN/m after ~50% of area compression (see also Table
S2). Addition of 4% (w/w) cholesterol to NS, either as
taking part of meconium or solubilized by MbCD, produced
a similar deleterious effect on the behavior of NS com-
plexes, which required an area compression of 50% to reach
surface tension of only around 20 mN/m (19.65 0.8 mN/m
for meconium- and 20.2 5 0.6 mN/m for cholesterol-
MbCD-treated surfactant; see Table S3). The inhibitory
effect of the exposure of surfactant to cholesterol-loaded
MbCD is clearly due to the increase in the proportion of
cholesterol produced in surfactant membranes, from 3% to
around 6% with respect to phospholipid (see above),
because exposure of surfactant to cholesterol-free cyclodex-
trine does not produce any effect on Q-static or dynamic
compression-expansion isotherms (see Fig. S1). Addition
of dextran or HA totally restored the behavior of NS films
during Q-static compression-expansion cycling: these
reached very low tensions with only ~20% area compression
even in the presence of serum, meconium, or cholesterol.
Fig. 6 confirms the differences in dynamic cycling
between inhibited and polymer/surfactant samples. Pres-
ence of a serum film resulted in NS reaching minimal
surface tension under dynamic cycling of 17.05 6.0 mN/m,
with an area reduction of 50%. Addition of 4% cholesterol
(w/w) contained in 10 mg/ml of meconium resulted in
minimal surface tension of 18.3 5 3.7 mN/m (area
compression 50%) and 4% cholesterol solubilized by
MbCD allowed NS to reach 7.2 5 4.0 mN/m (area
compression 30%). Despite the presence of the inhibitory
agents, the exposure of NS to either HA or dextran pre-
vented the inhibitory effects observed under dynamic
cycling, resulting in NS films that were completely func-
tional, with parameters that were similar to those exhibited
in the absence of inhibitors. The films were able to reach the
lowest surface tensions, statistically indistinguishable than
those reached in the absence of inhibitors, with practically
no hysteresis, needing only ~20% of area compression.DISCUSSION
In this study, we modified CBS protocols to study inhibition
of surfactant by several substances relevant to human lung
injury. Furthermore, we have documented the remarkable
ability of ionic (HA) and nonionic (dextran) polymers to
reverse not only serum inhibition of surfactant, but also
inhibition by meconium or cholesterol, two substancesBiophysical Journal 103(7) 1451–1459
FIGURE 5 Quasi-static compression-expansion cycling isotherms for surfactant injected under the bubble at the CBS, in the absence or in the presence of
serum, meconium, or cholesterol, combined or not with HA or dextran. A representative experiment is shown in each panel, after three repetitions from
each sample.
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serum.
The ability of surfactant to reach the interface in the
presence of inhibitors depends on surfactant concentration.
NS is highly surface active in very low concentrations
(10 mg/mL) and is resistant to inhibition at phospholipid
concentrations R20 mg/mL. In vivo, after lung injury,
relative concentrations of serum and other inflammatory
inhibitors and surfactant are difficult to ascertain and vary
over the course of the disease. Lung injury and concomi-
tant edema is associated not only with leakage of serum,
lipoproteins, cholesterol, and other inhibitory agents into
alveoli but also produces an effective dilution of the sur-
factant, which could be further reduced by impairment in
synthesis/secretion of new surfactant due to epithelium
damage.
Our data suggest that a decrease in concentrations of
surfactant below a certain threshold permits inhibition.
Therefore, one therapeutic strategy is to overcome inhibi-
tion associated with lung injury by the introduction of exog-
enous surfactant. However, previous work has shown thatBiophysical Journal 103(7) 1451–1459current clinical surfactants are substantially more suscep-
tible to inhibition than NS (6).
Our model confirms that serum can form an interfacial
barrier composed of serum proteins that impedes proper
adsorption of surfactant. This explains why minimal
tensions achieved by diluted surfactant are not much lower
than surface tensions produced by pure serum layers.
Surfactant fails to reach an interface that is previously occu-
pied by a concentrated layer of surface-active serum
proteins. Our results show that a brief disruption of the
serum layer caused by injecting surfactant at the bubble
surface can be enough to give surfactant the opportunity
to compete with serum components for adsorption into
a newly opened interface, thereby displacing serum proteins
to reach an (uninhibited) low tension. The concept of
competitive adsorption of serum and surfactant has been
developed in the inhibition models proposed by the Zasad-
zinski group (7,25–27). We show here that the mere
mechanical disruption of the inhibitory layer can also be
a crucial contribution to overcome surfactant inactivation
provided that surfactant is active enough to compete
FIGURE 6 Dynamic compression-expansion cycling isotherms for surfactant injected under the bubble at the CBS, in the absence or in the presence of
serum, meconium, or cholesterol, combined or not with HA or dextran. A representative experiment is shown in each panel, after three repetitions from each
sample.
Polymer Reversal of Surfactant Inhibition 1457efficiently with the less surface active but much more
concentrated serum components.
The addition of nonionic or anionic polymers such as
dextran or HA can improve substantially the resistance of
surfactant to inactivation. This activity of polymers had
been extensively documented (6,15,28–30), but not under
the restrictive conditions imposed in our assay. The action
of polymers has been explained by models that invoke poly-
mer-created depletion forces that push the large surfactant
complexes against the interface, thereby overcoming the
steric and electrostatic barrier imposed by serum layers
(6–8). Still, it is difficult to envision how depletion forces
can propel surfactant, injected far—in molecular terms—
below the interface, to cross the concentrated layer of serum
to reach the interface where surface-active species are
finally transferred. The polymers in our experiments are
restricted to the small volume of injected surfactant. After
injection of surfactant/polymer combinations, the polymers
are likely homogenously distributed and diluted into the
thin layer of fluid constituting the subphase, without a partic-ular accumulation at the interface, because injection of
equivalent amounts of polymer alone does not produce
apparent effects on surface tension. These conditions are
different from previously published work. In our experi-
ments the polymers are not included in the subphase, where
in principle they are diluted to concentrations much lower
than those required to promote depletion forces shortly after
injection of the surfactant/polymer mixtures. The ability of
the polymers to allow surfactant to successfully cross the
serum layer and adsorb at the interface is remarkable.
Preliminary experiments using a quartz-microbalance
model (31) discarded binding of HA to surfactant com-
plexes (not shown), indicating that the effect of HA to
promote interfacial adsorption in the presence of the serum
layer is not due to the formation of polymer/surfactant
complexes with particularly favorable surface properties.
It remains to be determined whether the establishment of
interactions between negatively charged polymers, such as
HA, and cationic protein components in serum, could
play a role in counteracting serum-promoted surfactantBiophysical Journal 103(7) 1451–1459
1458 Lo´pez-Rodrı´guez et al.inhibition. However, this possibility does not seem likely
because i), a nonionic polymer like dextran seems to
produce qualitatively similar effects, and ii), the total
amount of polymer introduced into the surfactant/polymer
combinations of our experiments is orders of magnitude
smaller than the amount of serum proteins in the surface
layer.
One would not have predicted that the addition of poly-
mers to surfactant mixtures would have a similar beneficial
effect after inhibition by meconium or cholesterol, which
acts by mechanisms that differ from true competitive
adsorption by serum proteins (9,10,32). These agents, meco-
nium and cholesterol, do not cause strong inhibition of
interfacial adsorption of surfactant, but rather cause a
substantial modification of its compression-expansion prop-
erties. This can be explained by insertion of the excess
of cholesterol into surfactant membranes and films, and
a concomitant reduction of their compressibility. Choles-
terol, solubilized either by bile salts (as in meconium) or
by MbCD, is transferred into surfactant films rendering
them dysfunctional during Q-static and dynamic cycles. It
seems that altered films experiment early collapse and do
not lower surface tension as a result of the incorporation
of 4% w/w cholesterol. Even though this is a relatively small
amount of cholesterol (33), it seems that in a soluble state
(in complexes with bile salts or MbCD) cholesterol has
a particularly notable deleterious effect.
Exposure to the polymers counteracts the perturbation of
rheological properties of surfactant caused by incorporation
of excess cholesterol. It is conceivable that a potential deple-
tion force-originated compaction of membrane structures,
with creation of extensive membrane-membrane interac-
tions, promotes a highly cohesive multilayered structure
that compensates for a loss of rigidity caused by an excess
of cholesterol-promoted fluidification. We have shown that
exposure to polymers such as dextran or HA do in fact create
compaction of surfactant structures and a generation of
membrane-based networks by different surfactant pre-
parations (34). We cannot discard the possibility that HA
would also interact with surfactant membranes and/or films
providing a surplus of mechanical stability compensating
the likely higher deformability of cholesterol-enriched
phases. The reversal or prevention of surfactant inhibition
by polymers has been extensively documented both
in vitro (25,30,35–37) and in vivo (35,38–40). The new, to
our knowledge, approach described here demonstrates that
certain polymers help NS overcome not only the inactivat-
ing effect of serum, but also that of meconium and choles-
terol. Thus, the reversion mechanism is general for NS
and not specific for inhibitory agents that we tested. We
are not aware of previous data showing that polymers not
only promote interfacial adsorption but also restore com-
pressibility of surfactant films during compression-expan-
sion cycling in the presence of inhibitors. Further studies
are required to analyze in more detail the ways in whichBiophysical Journal 103(7) 1451–1459polymers may structure and organize surfactant membranes
and films, particularly when surfactant has been pathologi-
cally altered. We speculate that exposure to polymers like
dextran or HA may induce an activation of surfactant by
modifying its structure so that it is much more resistant to
different types of inhibition and has better surface properties
in terms of both better interfacial adsorption and improved
rheological properties to sustain high pressures without
collapsing. If this is the case, addition or treatment with
polymers may produce new clinical surfactants for lung
injuries for which there is as yet not good therapy.
In summary, to our knowledge, the novel conditions of
our experiments may mirror the introduction of therapeutic
surfactant into edematous alveoli that are replete with
inflammatory inhibitors after acute lung injuries. Our results
affirm the potential use of certain polymers as useful addi-
tives to therapeutic surfactants.SUPPORTING MATERIAL
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